Track topics on Twitter Track topics that are important to you
UK biotechnology firm Ixchelsis has achieved positive clinical proof of concept (POC) for IX-01, its oral oxytocin receptor antagonist being developed to treat premature ejaculation (PE).
Sandwich, UK, January 25, 2016 / B3C newswire / -- Ixchelsis Ltd, a UK based biotech company, announced today that it has achieved positive clinical proof of concept (POC) for IX-01, its oral o...
(CNN) – Planned Parenthood filed a lawsuit Thursday against the anti-abortion activists who secretly taped the group’s officials talking about the sale of fetal tissue and released the hea...
Check out these six short videos, courtesy of Be Smart. Be Well., with important health messages about sexually transmitted diseases (STDs).
Lawsuit says the hospital recorded 15,000 videos and that the videos were watched by security guards.
Premature ejaculation is one of the prevalent disorders in men; almost one out of three men between 18 and 59 years old have this disorder with its leading sequel such as lack of self-confidence, anxi...
Four premature ejaculation (PE) subtypes are distinguished on the basis of the duration of the intravaginal ejaculation latency time (IELT), its course in life, and frequency of complaints. Since the ...
Premature ejaculation is one of the most common male sexual dysfunctions; however, only a few patients with premature ejaculation are seeking professional help or advice. Internet has become an import...
Premature ejaculation (PE) is the most prevalent male sexual dysfunction. In the last few years, several pharmacologic approaches for oral or topical treatment of PE have been studied.